Country: Canada
Language: English
Source: Health Canada
ANTITHROMBIN III (HUMAN); WATER
BAXTER AG
B01AB02
ANTITHROMBIN
1650UNIT; 30ML
POWDER FOR SOLUTION
ANTITHROMBIN III (HUMAN) 1650UNIT; WATER 30ML
INTRAVENOUS
1350-1650 IU/VIAL
Schedule D
DIRECT THROMBIN INHIBITORS
Active ingredient group (AIG) number: 0224213003; AHFS:
CANCELLED POST MARKET
2011-10-07
PRODUCT MONOGRAPH ANTITHROMBIN III IMMUNO ANTITHROMBIN III (HUMAN), E.P. 450 - 550 lU 1 /10 mL, 900 - 1100 lU 1 /20 mL, 1350 -1650 IU 1 /30 mL Freeze-dried powder with diluent for intravenous injection/infusion Anticoagulant Manufactured by: BAXTER AG A-1220 Vienna, Austria Imported and Distributed by: Date of Revision: January 6, 2010 BAXTER CORPORATION 4 Robert Speck Parkway, Suite 700 Mississauga ON Canada L4Z 3Y4 Date of Approval: June 9, 2010 Submission Control #: 137766 ANTITHROMBIN III IMMUNO ANTITHROMBIN III (HUMAN), E.P. 450 - 550 lU 1 /10 mL, 900 - 1100 lU 1 /20 mL, 1350 -1650 IU 1 /30 mL Freeze-dried powder with diluent for intravenous injection/infusion Anticoagulant ACTION AND CLINICAL PHARMACOLOGY Antithrombin III acts as a physiological inhibitor of blood coagulation, particularly by inhibition of thrombin and activated factor X, but also of factors lXa, XIa, XIIa, and plasmin. This inhibitory effect of antithrombin III (AT III) can occur in the absence of heparin, but is accelerated within the presence of heparin. Antithrombin III is an alpha-2 globulin with a molecular weight ranging between 58,000 and 65,000 dalton. Plasma concentrations from 140 μg to 300 μg /mL have been reported in healthy adults. In adults, the normal range of activity is between 80 and 120%, where 100% is equivalent to the antithrombin III activity as found in 1 mL of a human reference plasma pool. Normal levels in newborns are approximately 50%. Adult levels are usually reached by six months of life. The fact that antithrombin III has a considerably reduced tolerance range compared to the coagulation factors is of clinical importance. Whereas the coagulation enzymes may drop to 40% and below without the occurrence of bleeding, even moderate decreases of antithrombin III activity to 70% are associated with an increased risk of thrombosis. ANTITHROMBIN III IMMUNO, Antithrombin III (human), provides a temporary increase in plasma levels of AT III and thus allows for treatment and/or prophylaxis of thrombotic or thromboembol Read the complete document